OFATUMUMAB (Kesimpta) prior authorization at EmblemHealth
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
EmblemHealth requires CD20-directed Cytolytic Antibody prior-authorization documentation for OFATUMUMAB (Kesimpta): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
EmblemHealth reviews OFATUMUMAB (Kesimpta) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody. EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- EmblemHealth's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- HIP HMO referral denials
- GHI PPO out-of-network reductions (NYC municipal employee plan)
- Behavioral health prior auth
- Specialty drug PA
OFATUMUMAB (Kesimpta)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring oral DMT first
- Step therapy requiring ocrelizumab first within anti-CD20 class
- Self-administration concerns
- Specialty pharmacy network restriction
Brand: Kesimpta. Anti-CD20 monoclonal antibody for relapsing MS. Self-administered monthly subQ — distinct positioning vs ocrelizumab (IV every 6 months).
Manufacturer patient-assistance program: Novartis Patient Assistance Foundation — relevant when an EmblemHealth denial sticks and the patient needs bridge access while appealing.
How EmblemHealth approaches Biologic drugs (mAbs and biosimilars) PAs
For OFATUMUMAB (KESIMPTA), check whether the current EmblemHealth Biologic drugs (mAbs and biosimilars) policy cites specialty drug pa. Pharmacy-benefit review for OFATUMUMAB (KESIMPTA) at EmblemHealth is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with EmblemHealth; if denied, use the filing date and route printed on that denial notice. EmblemHealth's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. EmblemHealth is domiciled in NY, so unresolved appeals escalate to the NY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.emblemhealth.com/providers) with the same packet plus an applicable, current clinical source supporting OFATUMUMAB (Kesimpta)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an EmblemHealth denial on DenialHelp.
Contact EmblemHealth
- Provider portal: https://www.emblemhealth.com/providers
Frequently asked questions
What documentation does EmblemHealth need for OFATUMUMAB (Kesimpta) prior auth?
EmblemHealth's typical PA packet for OFATUMUMAB (Kesimpta): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at EmblemHealth?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OFATUMUMAB (Kesimpta) at EmblemHealth?
Preparation scenarios to check against the current notice and policy include: HIP HMO referral denials; GHI PPO out-of-network reductions (NYC municipal employee plan); Behavioral health prior auth. These are not measured frequency claims. For OFATUMUMAB (Kesimpta), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does EmblemHealth typically require before approving OFATUMUMAB (KESIMPTA)?
EmblemHealth's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For OFATUMUMAB (KESIMPTA), attach the specific disease-activity instrument EmblemHealth accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for EmblemHealth fully-insured policies sits with the NY insurance department.
How do I prep for a peer-to-peer with EmblemHealth on OFATUMUMAB (Kesimpta)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OFATUMUMAB (Kesimpta) PA packet
Open ApprovalHelp — generate a OFATUMUMAB (Kesimpta) prior-auth packet tailored to EmblemHealth's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com